Table 4.
Second-line treatment, n (%) |
nab-Paclitaxel plus carboplatin (n = 26) |
Gemcitabine plus carboplatin (n = 61) |
---|---|---|
Docetaxel | 1 (4) | 24 (39) |
Gemcitabine | 9 (35) | 1 (2) |
Paclitaxel plus carboplatin | 3 (12) | 7 (11) |
Paclitaxel | 2 (8) | 7 (11) |
nab-Paclitaxel plus carboplatin | – | 8 (13) |
Other | 11 (42) | 14 (23) |